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joints (P=0.004). OC injured SF C2C concentrations were posi-
tively correlated with radiographic scores (R=0.43; P=0.03) and
arthroscopic scores (R=0.52; P=0.03). Arthroscopic scores were
positively correlated with radiographic scores (R=0.51; P=0.04).
SF C2C concentrations ≥ 64 pmol/mL for MCP/MTP joints and ≥
75 pmol/mL for carpal joints were arbitrarily chosen to determine
predictive value for discriminating OC injured horses from rested
or exercised horses. This yielded a positive predictive value of
73% and a negative predictive value of 94% for the MCP/TP
joints, and positive predictive value of 79% and negative predic-
tive value of 95% for the carpus.
Conclusions: OC injury caused a signiﬁcant increase in SF
C2C concentrations in carpal and MCP/MTP joints compared
to rested and exercised horses. SF C2C concentrations were
correlated to severity of joint injury. Based on these ﬁndings, SF
C2C analysis may be useful for evaluation of joint injury.
Acknowledgment: Study supported in part by the University of
Florida Equine Soundness Program.
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FOLLOW-UP OF COLL2-1, COLL2-1NO2 AND
MYELOPEROXYDASE SERUM LEVELS IN MARATHON
RUNNERS
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Y. Henrotin1
1University of Liège, Liège, Belgium; 2Zentech, Liège, Belgium
Purpose: To determine the inﬂuence of marathon on the serum
levels of two markers of cartilage degradation, Coll2-1, a peptide
of type II collagen triple helix, and its nitrated form, Coll2-1NO2,
and of a marker of neutrophils activation, the myeloperoxidase
(MPO).
Methods: Coll2-1, Coll2-1NO2 and MPO were measured by
speciﬁc immunoassays in 66 marathon runners without joint
pain and aged in mean of 47 (min: 31 - max: 59) years. Sera
were taken before and after the marathon. All the subjects were
submitted to a questionnaire concerning their physical activity
(i.e. training or best performance) and their life style (i.e; diet).
The total running distance was 42 km. Their performance in the
marathon was ranged from 149 to 270 min.
Results: Before the marathon, the Coll2-1 and Coll2-1NO2 val-
ues were not affected by age, body mass index, sex and per-
formance [Coll2-1 median: 90.66 (28.77-234.68) nM and Coll2-
1NO2 median: 0.16 (0.05-0.71) nM], while MPO levels were
higher in female [median: 41.3 (29.90-96.50) ng/ml] than in
male [median: 33.00 (15.60-84.60) ng/ml] (p<0.05). After the
marathon, Coll2-1 levels were slightly decreased [median: 76.63
(28.89-185.06) nM], Coll2-1NO2 levels were unmodiﬁed [median:
0.15 (0.05-0.61) nM] and MPO levels were doubled [median:
71.80 (31.50-172.10) ng/ml] compared to the pre-marathon val-
ues [MPO median: 34.20 (15.60-96.50) ng/ml] (p<0.001). The
variation of MPO during the marathon was negatively correlated
with the training time per week (r=-0.36; p=0.0045). Before the
marathon, there was no correlation between the different biolog-
ical markers (Coll2-1, Coll2-1NO2 and MPO).
Conclusions: Coll2-1 and Coll2-1NO2 serum levels were not
modiﬁed by marathon, suggesting that, at least at short-term,
this intensive physical activity does not signiﬁcantly modiﬁed
cartilage metabolism. Interestingly, serum MPO levels were in-
creased after the marathon and training reduced this elevation.
These results suggest that neutrophils were activated during the
marathon and that training reduces neutrophils activation during
the marathon.
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QUANTITATIVE WESTERN BLOTTING SHOWS
DIFFERENCES IN SYNOVIAL FLUID AGGRECAN
FRAGMENT PATTERNS BETWEEN HUMAN JOINT
DISEASES
A. Struglics, S. Larsson, M. Hansson, S. Lohmander
Lund University, Lund, Sweden
Purpose: Aggrecan proteolysis is an early key event in arthritis.
Aggrecanases cleave the interglobular domain of aggrecan re-
leasing N-terminal ARGS fragments, and the chondroitin sulfate
rich domain releasing C-terminal G3 domain fragments. Several
reports suggest a role for more than one ADAMTS activity and
possibly other proteases in the release of aggrecan fragments
from joint cartilage. Differences between animal models and hu-
man disease, and differences between human joint diseases
and disease stages suggest a role for a method to map in detail
aggrecan proteolytic fragments in multiple samples. We have
developed a quantitative Western blot method for analysis of
aggrecan fragment patterns in synovial ﬂuids (SF) from patients
with different joint diseases.
Methods: Dissociative CsCl gradient centrifugation was used
for sample preparation from SF of 5 knee-healthy subjects (ref-
erence) and 27 patients with 4 different knee joint diseases.
Aggrecan fragments (D1-fractions) separated by SDS-PAGE and
transferred to PVDF membranes were screened, using a digi-
tal luminescence imager, with an ARGS neo-epitope antibody
or an antibody recognizing the G3-domain. ARGS-standards
were generated by complete aggrecanase digestion of intact hu-
man aggrecan. Quantiﬁcation was by co-running either ARGS-
standards or a control sample (in G3 quantiﬁcation) on each
SDS-gel. Results were compared and expressed as mol (ARGS)
or relative AU (G3) per mg glycosaminoglycan (GAG) determined
by Alcian Blue precipitation.
Results: GAG recovery in D1-fractions was >75%, and West-
ern blot CVs between experiments for anti-ARGS and anti-G3
were 19% and 28%. Total ARGS fragment quantity in SF sam-
ples by Western blot correlated well with ARGS-ELISA (R2=0.87,
n=19), while the correlation between ARGS and GAG content
was only moderate (R2=0.31, n=31). SFs contained two major
ARGS-bands, ARGS-SELE and ARGS-GVED, and three major
G3-bands (GRGT-G3, GLGS-G3 and AGEG-G3) as a result of
aggrecanase proteolysis. Median values of total ARGS fragments
in the diagnostic groups were signiﬁcantly higher in the acute
arthritis and acute injury groups compared to the reference,
and these SF samples contained the highest total ARGS values
per mg GAG (Table 1; *P<0.05; **P<0.01 compared to refer-
ence). The differential between reference and disease groups
was greatest for the ARGS-SELE fragment. Median values of
total G3 per mg GAG were signiﬁcantly lower in the acute arthri-
tis and osteoarthritis groups than in the reference. The ratios of
total-ARGS to total-G3 fragments varied markedly between the
diagnostic groups.
Table 1. Western blot analysis in diagnostic groups. Median values normalized
to reference
Group n ARGS- ARGS- Total Total Total
SELE GVED ARGS G3 ARGS/G3
Reference 5 1 1 1 1 1
Acute arthritis 8 25** 10.1** 10.7* 0.5* 22.3*
Acute injury 9 20.2** 10.2** 10* 0.6 9.5**
Chronic injury 5 4.2 2.2 2.1 1.2 0.9
Osteoarthritis 5 8.4 2.9 3.4 0.3* 2.6
Conclusions: We have developed a quantitative Western blot
method for aggrecan fragment screening of synovial ﬂuids. It
provides reliable results as judged by relatively low CV and good
correlation between Western and ELISA methods. Anti-ARGS
C68 Poster Presentations
and anti-G3 quantitative Western blot showed aggrecan fragment
patterns for individual subjects, allowing a detailed comparison
of aggrecan proteolysis in different human joint diseases and dis-
ease stages. SF aggrecan fragment patters differed signiﬁcantly
between different human joint diseases, suggesting differences
in protease activity and or structure of the cartilage matrix sub-
strate. Use of additional antibodies will allow quantiﬁcation of
other aggrecan fragments. The method can help identify new OA
biomarkers. It is also suitable for in vitro screening of protease
inhibitors and in early development of disease modifying therapy
of human joint diseases.
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BIOLOGICAL VARIABILITY OF BIOCHEMICAL MARKERS
OF BONE, CARTILAGE AND SYNOVIAL METABOLISM IN
PATIENTS WITH KNEE OSTEOARTHRITIS: EFFECT OF
FOOD INTAKE
P. Garnero1, I.S. Gourley2, E. Mareau3, B.L. Durn2, L. Hickey2,
S. Cohen4
1Inserm Unit 664 and Synarc, Lyon, France; 2Wyeth Research,
Collegeville, PA; 3Synarc, Lyon, France; 4St.Paul/UT,
Southwestern University Hospital, Dallas, TX
Purpose: Biochemical markers (BM) may be useful to assess
disease progression and efﬁcacy of treatments in osteoarthritis
(OA). The clinical utility of BMs depends on two components: 1)
their sensitivity to detect changes with disease or treatment and
2) their biological variability which may be affected by food intake.
The aim of this study was to evaluate the effect of food intake on
the concentration and the between day intra-subject variability of
BMs in untreated patients with knee OA and in healthy subjects
of similar age.
Methods: We recruited 22 patients (13 women, 9 men, mean
age 58 yr) with radiographic knee OA (12 with Kellgren-Lawrence
[KL] score 2 and 10 with KL score 3) and 10 healthy subjects
(7 women, 3 men, mean age: 47 yr) with no radiographic OA
at the knees, hips and spine. No subject was treated with any
investigational OA drugs, estrogen or bisphosphonate within the
previous 3-6 months and during the 14 days study period. When
receiving NSAIDs and/or dietary supplements, no change in
therapy was permitted during the study. For each subject and
at each of the 3 visits (day 1, day 7 and day 14), morning
blood samples were collected at two time points: fasting (F) at
7.45 before an 8.00 breakfast and non-fasting (NF) at 10.00,
2 hours after breakfast. Second morning void urine was also
collected at each 3 visits. The following serum (S) and urine
(U) BMs were measured: S-CTX-I, a BM of bone resorption,
S-COMP, a BM of cartilage turnover, S-PIIANP, a BM of cartilage
synthesis, hyaluronic acid (S-HA), a BM of synovitis, U-CTX-II,
a BM of cartilage degradation and U-Glc-Gal-PYD, a BM of
synovial tissue metabolism. For S-BMs, the difference in levels
between NF and F state was calculated and the intra-subject
variability was estimated by mixed model ANOVA.
Results: Patients with knee OA had higher median levels of S-
COMP (+30%, p=0.02 and +24%, p=0.05 for F and NF samples,
respectively), S-HA (+48%, p=0.02 and +13%, p=0.12 for F
and NF samples) and CTX-II (+108%, p<0.01) than healthy
controls. Patients with knee OA KL score 3 had higher F-levels
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S-CTX-I S-COMP S-PIIANP S-HA
% NF-F CVi-F CVi-NF %NF-F CVi -F CVi -NF % NF-F CVi -F CVi -NF % NF-F CVi -F CVi-NF
All -52%** 12.9 28.6 0.1% 8.8 8.8 -2.0% 19.7 25.1 +33%** 34.3 34.2
Knee OA -52%** 12.5 29.8 -0.1% 8.5 8.9 -1.9% 19.6 25.7 +30%** 36.1 37.0
Healthy -51%* 13.0 23.9 0.4% 9.2 8.0 -8.9% 20.4 20.6 +45%* 19.7 22.0
*p<0.01, **p<0.001.
of S-CTX-I (+64%, p=0.02), S-COMP (+37%, p=0.02), S-HA
(+68%, p=0.03), U-CTX-II (+151%, p<0.001) and U-Glc-Gal-
PYD (+53%, p=0.01) than patients with KL-2. When measured
on NF samples, the difference between patients with KL-2 and
KL-3 was not anymore signiﬁcant for S-CTX-I and S-HA. The
table shows the difference of S-BM levels in NF compared with F
state as a percentage (% NF-F) and the intra subject coefﬁcient
of variation (CVi%) in all subjects, in patients with knee OA, and
in healthy controls and in F (CVi-F) and NF (CVi-NF) conditions.
For urinary markers, the intra-subject variability in all subjects,
knee OA patients and healthy controls were respectively 23.1%,
19.6% and 30.5% for U-CTX-II and 21.1%, 22.3% and 16.4% for
U-Glc-Gal-PYD.
Conclusions: Food intake has a marked inﬂuence on the levels
of S-CTX-I and S-HA and increases variability of S-CTX-I, but has
small effects on S-COMP and S-PIIANP. The association of S-
BMs with OA was higher when measured on F than NF samples.
Standardized collection of fasting sample is recommended for
measuring BM in OA.
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PATIENTS WITH RHEUMATOID ARTHRITIS HAVE AN
ALTERED AGGRECAN PROFILE IN SERUM
E.U. Sumer1, J-C. Rousseau2, G. Hein3, S.H. Madsen1,
B-C. Sondergaard1, P. Qvist1, C. Pedersen4, C. Christiansen1,
T. Neumann3, P.D. Delmas5, M.A. Karsdal1
1Nordic Bioscience, Herlev, Denmark; 2Inserm Unit 831, Lyon,
France; 3Friedrich-Schiller-Universitat, Jena, Germany;
4Orthopaedic Surgery Unit Nordjylland, Farsoe, Denmark;
5Inserm Unit 403 and Synarc, Lyon, France
Purpose: Rheumatoid Arthritis (RA) is a chronic auto-immune
disease with aggressive and extensive articular cartilage destruc-
tion. Aggrecan is the major proteoglycan of articular cartilage,
and is composed of three globular domains (G1-G3). Aggrecan
depletion, mediated by aggrecanases is one of the ﬁrst signs of
early cartilage erosion. We investigated, whether measurement
of aggrecan and fragments thereof in serum, could be used as
biomarkers for joint-disease in RA patients.
Methods: For the veriﬁcation of release of intact aggrecan and
degradation fragments, we used catabolically stimulated human
cartilage explants from a late stage 42 year old female patient
with osteoarthritis (OA). Pieces of cartilage (12-16 mg) were
placed in 96 well plates in 4-replicates and incubated for 21
days at 37°C with 5% CO2 and shaking (50 rpm). Serum-free
D-MEM medium was used. Explants were incubated with either
medium alone, or 10 and 20 ng/ml of the pro-inﬂammatory
cytokines OSM/TNFα respectively. As negative control, cartilage
was placed in cryo-tubes, frozen in liquid N2 and thawed at 37°C
in water-bath for three repeated freeze-thaw cycles. The explant
culture medium was replaced every 3rd day for 21 days.
The study co-hort consisted of 108 healthy individuals and 38
patients diagnosed with RA (61.3±19.3 years, 71.05 ±14.5
kg, 4.7±1.6 disease activity score). Aggrecan levels were in-
vestigated by, 1) 374ARGSVI-G2 sandwich assay measuring
aggrecanase-mediated aggrecan degradation, or 2) G1/G2 sand-
wich assay, believed to account for the total turnover of aggre-
can. We further characterised serum samples by western blots,
